HOME >> BIOLOGY >> NEWS
Using lasers, biologists succeed in getting cells to change course

CHAPEL HILL - Most people probably think that most cells in the body -- not counting blood cells -- stay in one place their entire lives just as whole plants do, but nothing could be further from the truth.

These microscopic living structures move a little or a lot, healing wounds, developing embryos, scouting and attacking disease-causing invaders and, sometimes, spreading cancer. As a result, the mechanics and chemistry of how cells get themselves from one place to another fascinates researchers around the world.

Now, using a beam of laser light only a few microns in diameter, University of North Carolina at Chapel Hill scientists have succeeded for the first time in getting such light to alter the course of a moving cell. They have accomplished that by having the laser create active proteins from what are called "caged" proteins that they introduced into the cell.

A report on the research appears in the May 28 issue of the Journal of Cell Biology.

The work has begun attracting attention from other scientists internationally.

"We put caging groups on particular amino acids of the protein we were interested in inside single cells and that makes the proteins less active," said Dr. Kenneth A. Jacobson, professor of cell and developmental biology at the UNC School of Medicine. "Then we directed the laser beam into part of the cells to break the bond between the caging group and the amino acid so that the protein became active again. Afterward, depending on where we shined the light, cells turned by as much as 90 degrees."

Their experiments might be likened to putting the breaks on one rear wheel of a car so that the car would tend to pull to one side or another, Jacobson said.

Besides Jacobson, UNC authors are Drs. Partha Roy, a postdoctoral fellow soon to join the research faculty, and Zenon Rajfur, research associate. Drs. Gerard Marriott and Leslie Loew of the universities of Wisconsin and Connecticut, respectively,
'"/>

Contact: David Williamson
David_Williamson@unc.edu
919-962-8596
University of North Carolina at Chapel Hill
21-Jun-2001


Page: 1 2

Related biology news :

1. Using statistics to decipher secrets of natural mutation
2. Using science to restore habitat for declining species
3. Using soils as filters to prevent crypto from moving to the groundwater
4. Using a companion crop to control weeds organically
5. Using plants and microbes to purify polluted industrial wastewater
6. Using GPR to estimate tree root biomass
7. Using computational power tools to bolster systems biology
8. Using RNA interference to tune gene activity in stem cells
9. Using sewage sludge as fertilizer
10. Using the oceans living light shows to fight terrorism or track the planets most massive migration
11. Using genetic research to treat inflammatory diseases Vienna centre of excellence in biomedicine harnesses basic research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Using lasers biologists succeed getting cells change course

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: